Drugs / Leramistat
Leramistat
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02480946 | Jul 2015 → Mar 2017 | rheumatoid arthritis | Modern Biosciences Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05951296 | Aug 2023 → Feb 2024 | idiopathic pulmonary fibrosis | Modern Biosciences Ltd | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05460832 | Aug 2022 → Dec 2023 | rheumatoid arthritis | Modern Biosciences Ltd | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06379958 Comparator | Apr → Sep 2024 overdue | — | Modern Biosciences Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT03139136 Comparator | May 2017 → Nov 2018 | rheumatoid arthritis | Modern Biosciences Ltd | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leramistat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05951296 ↗ |
| Known as | HMC-C-01-A | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314525 ↗ |
| Known as | MBS2320 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02480946 ↗ |
| Modality | Small molecule | — CHEMBL5314525 ↗ |
| Route | Oral | “MBS2320 is administered orally as single and multiple doses” NCT02480946 ↗ |